Boehringer Ingelheim agrees to pay $650 Million to compensate the nearly 4,000 individuals who allege they were injured as a result of Pradaxa usage.
Online PR News – 29-May-2014 – Chicago, IL – TorHoerman Law is pleased to announce that the Pradaxa litigation that it has helped lead since before the Multi-District Litigation (MDL) was formed is set to be resolved by settlement. Boehringer Ingelheim, which manufactures the drug, and lead plaintiffs’ counsel, including Tor Hoerman, reached an agreement yesterday that will resolve all pending lawsuits in the United States, as well as a large number of as-yet-unfiled cases. The Pradaxa settlement will compensate plaintiffs who allege that they were injured, most commonly by severe bleeding events, as a result of their use of Pradaxa. Boehringer Ingelheim has not admitted wrongdoing.
Tor Hoerman was appointed as Plaintiffs’ Co-Lead Counsel shortly after the MDL was formed, and in that role, was responsible for shepherding the litigation to this point. Hoerman was also appointed as one of Plaintiffs’ Negotiating Counsel and worked to secure the settlement announced today. “This settlement allows those who believe they were injured by Pradaxa to receive fair compensation for their claims,” Hoerman said. “We appreciate that the defendants did the right thing, we congratulate the lawyers that worked so hard to achieve this settlement, and we look forward to continuing our work to see that the plaintiffs receive the compensation to which they are entitled under the terms of the settlement.”
Nearly 4,000 cases are eligible to participate in the settlement of $650,000,000.00. The settlement was announced less than two years after the MDL was formed. The MDL is pending in the United States District Court, Southern District of Illinois, and is overseen by Chief Judge David R. Herndon.